People who smoke cigarettes have an increased risk of developing emphysema, heart disease, and certain types of cancer. This study will evaluate the effectiveness of providing free nicotine patches from an online smoking cessation program, with and without telephone counseling, at improving quit rates in cigarette smokers...
Date First Received: September 21, 2007
Last Updated: February 26, 2009
Verified by: National Heart, Lung, and Blood Institute (NHLBI), February 2009
Clinical Trial Phase: N/A | Start Date: July 2009
Overall Status: Not yet recruiting
Estimated Enrollment: 2475
Brief Summary
Official Title: “A Randomized Trial of Internet Access to Nicotine Patches”
Condition Keyword(s):
People who smoke cigarettes have an increased risk of developing emphysema, heart disease, and certain types of cancer. This study will evaluate the effectiveness of providing free nicotine patches from an online smoking cessation program, with and without telephone counseling, at improving quit rates in cigarette smokers.
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Study Primary Completion Date: December 2012
Detailed Clinical Trial Description
Tobacco use is the single most preventable cause of death in the United States, with cigarette smoking accounting for nearly one-third of all cancer deaths each year. Although a number of inexpensive and effective smoking cessation methods exist, including the nicotine patch and nicotine gum, smoking rates have not declined in the past few years. More than 8 million people in this country use the Internet to seek assistance with quitting smoking.
Research suggests that people who use interactive smoking cessation Web sites typically only experience a short period of smoking abstinence. Smokers who receive nicotine patches in addition to online assistance are more than twice as likely to quit smoking. The purpose of this study is to evaluate the effectiveness of a combination of free nicotine patches and an online smoking cessation program, with and without access to telephone counseling, at improving smoking cessation rates in cigarette smokers.
This study will enroll people who accessed the Quitnet.com Web site. Participants will complete a baseline survey about their smoking habits and quit history. Participants will then be randomly assigned to one of the following three treatment groups: - Group 1 participants will receive free access to nicotine patches, telephone counseling, and Quitnet.com services. - Group 2 participants will receive free access to nicotine patches and Quitnet.com services. - Group 3 participants will receive Quitnet.com services.
Participants receiving telephone counseling will receive three phone calls over a 2-week period to discuss their personal smoking cessation plan; they must complete all three calls in order to receive the nicotine patches. At Months 1, 3, and 9, all participants will complete online surveys about their smoking cessation experience. Participants will be contacted by phone to complete the surveys if they do not complete them online.
Intervention(s) in this Clinical Trial
- Drug: Nicotine patches
- Participants will wear nicotine patches.
- Behavioral: Telephone counseling
- Participants receiving telephone counseling will receive three phone calls over a 2-week period to discuss their personal smoking cessation plan.
- Behavioral: Quitnet.com Web site
- Participants will access the Quitnet.com Web site.
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: Nicotine Patches, Telephone Counseling, and Internet
- As adjuncts to an internet-assisted tobacco treatment website, research participants in this arm will have access to free 8-week supply of nicotine patches, contingent upon participation in proactive telephone counseling. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
- Active Comparator: Nicotine Patches and Internet
- As adjuncts to an internet-assisted tobacco treatment, research participants in this arm will have access to free 8-week supply of nicotine patches. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
- Placebo Comparator: Internet
- Research participants in this arm will have free access to internet-assisted tobacco treatment website.
Outcome Measures for this Clinical Trial
Primary Measures
- Self-reported 6-month prolonged abstinence from smoking
- Time Frame: Measured at Month 9
Safety Issue?: No
- Time Frame: Measured at Month 9
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Currently smokes 10 or more cigarettes per day
- Actively searching online for smoking cessation assistance on the Quitnet.com Web site
- Does not use any tobacco products other than cigarettes
- Willing to set a quit date within 2 to 4 weeks following study entry
- Willing to use a nicotine patch
- Able to speak English
- Access to Internet, email, and telephone at work or home
- Resident of the United States
- Only one person per household is eligible to enroll
Exclusion Criteria:
- Medically unable to use the nicotine patch (e.g., pregnant, history of a heart attack)
- Currently uses nicotine replacement therapy (NRT) products
- Currently uses or plans to use Bupropion SR, Wellbutrin, or Zyban
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Overall Clinical Trial Officials and Contacts
Larry C. An, MD Principal Investigator University of Minnesota
Overall Contact: Larry C. An, MD 612-624-6925 lcan@umn.edu
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00534404
Study ID Number: 511
ClinicalTrials.gov Identifier: NCT00534404
Health Authority: United States: Federal Government
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.